share_log

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $125

Benzinga Real-time News ·  Jan 27, 2023 07:44

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $122 to $125.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment